文献速递肿瘤 PET/CT

PET缓解联合基线代谢肿瘤体积对外周T细胞淋巴瘤患者的预测价值

Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients.
PubMed 文献 · J Nucl Med · 2017-09-01

该研究从7个欧洲中心纳入140例外周T细胞淋巴瘤(PTCL)患者,评估PET/CT缓解联合基线总代谢肿瘤体积(TMTV)能否早期发现复发或难治性疾病。中位随访43个月,2年无进展生存(PFS)率和总生存(OS)率分别为51%和67%。中期PET阳性(Deauville评分≥4)患者预后显著更差,联合TMTV与iPET3/4可将患者分层为不同风险组。

要点

  • iPET2阳性(Deauville评分≥4)患者PFS的HR为6.8(P<0.0001),OS的HR为6.6(P<0.0001)。
  • iPET3/4阳性(n=28)与阴性(n=67)患者的2年PFS率分别为16%和75%,2年OS率分别为32%和85%。
  • TMTV≤230 cm3且iPET3/4阴性者2年PFS/OS为79%/85%,TMTV>230 cm3且iPET3/4阳性者为0%/18%。

核心结论

  • iPET缓解可预测PTCL患者结局,有助于早期识别高危患者。
  • iPET联合TMTV可改善个体患者的风险分层。

研究设计与样本

  • 从7个欧洲中心选取140例接受基线PET/CT的结节性PTCL患者。
  • 43例在2个周期后行iPET2,95例在3或4个周期后行iPET3/4,96例行治疗结束PET(eotPET)。
  • 基线TMTV采用41% SUVmax阈值计算,PET缓解采用Deauville 5分量表评估。

主要发现

  • 中位随访43个月,2年PFS率和OS率分别为51%和67%。
  • iPET2阳性(Deauville评分≥4)患者较阴性患者PFS更差(P<0.0001,HR 6.8),OS更差(P<0.0001,HR 6.6)。
  • iPET3/4对PFS(P<0.0001)和OS(P<0.0001)的预测价值得到确认。
  • iPET3/4阳性(n=28)与阴性(n=67)患者的2年PFS率分别为16%和75%,2年OS率分别为32%和85%。
  • eotPET结果也反映患者结局。

关键数值与推荐

  • TMTV≤230 cm3且iPET3/4阴性:2年PFS/OS为79%/85%。
  • TMTV>230 cm3且iPET3/4阴性:2年PFS/OS为59%/84%。
  • TMTV≤230 cm3且iPET3/4阳性:2年PFS/OS为42%/50%。
  • TMTV>230 cm3且iPET3/4阳性:2年PFS/OS为0%/18%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes on current therapy. We investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refractory disease. Methods: From 7 European centers, 140 patients with nodal PTCL who underwent baseline PET/CT were selected. Forty-three had interim PET (iPET) performed after 2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4), and 96 had end-of-treatment PET (eotPET). Baseline TMTV was computed with a 41% SUVmax threshold, and PET response was reported using the Deauville 5-point scale. Results: With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS) were 51% and 67%, respectively. iPET2-positive patients (Deauville score ≥ 4) had a significantly worse outcome than iPET2-negative patients (P < 0.0001, hazard ratio of 6.8 for PFS; P < 0.0001, hazard ratio of 6.6 for OS). The value of iPET3/4 was also confirmed for PFS (P < 0.0001) and OS (P < 0.0001). The 2-y PFS and OS for iPET3/4-positive (n = 28) and iPET3/4-negative (n = 67) patients were 16% and 32% versus 75% and 85%, respectively. The eotPET results also reflected patient outcome. A model combining TMTV and iPET3/4 stratified the population into distinct risk groups (TMTV ≤ 230 cm3 and iPET3/4-negative [2-y PFS/OS, 79%/85%]; TMTV > 230 cm3 and iPET3/4-negative [59%/84%]; TMTV ≤ 230 cm3 and iPET3/4-positive [42%/50%]; TMTV > 230 cm3 and iPET3/4-positive [0%/18%]). Conclusion: iPET response is predictive of outcome and allows early detection of high-risk PTCL patients. Combining iPET with TMTV improves risk stratification in individual patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cottereau AS, El-Galaly TC, Becker S, et al. Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. J Nucl Med. 2017. PMID: 28864629. doi:10.2967/jnumed.117.193946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。